IMFINZI Emerging Drug Insight

“IMFINZI Market Size, Forecast, and Drug Insight – 2032” report provides both market as well as emerging insights about IMFINZI for the treatment of cholangiocarcinoma and malignant pleural mesothelioma in the seven major markets. A detailed picture of the IMFINZI in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019–2032 is provided in this report along with a detailed description of the IMFINZI. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the IMFINZI market forecast, analysis in the 7MM descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies.

Drug Summary

IMFINZI (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumor’s immune-evading tactics and releasing the inhibition of immune responses. It is known as a checkpoint inhibitor drug.

Inflammatory signals can induce the expression of programmed cell death ligand-1 (PD-L1) (e.g., IFN-gamma) and can be expressed on both tumor cells and tumor-associated immune cells in the tumor microenvironment. PD-L1 blocks T-cell function and activation through interaction with PD-1 and CD80 (B7.1). By binding to its receptors, PD-L1 reduces cytotoxic T-cell activity, proliferation, and cytokine production. Blockade of PD-L1/PD-1 and PD-L1/CD80 interactions releases immune responses inhibition, without inducing antibody-dependent cell-mediated cytotoxicity (ADCC).

AstraZeneca’s IMFINZI (durvalumab) has been approved in the US for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin). The approval by the Food and Drug Administration (FDA) was based on the results from the TOPAZ-1 Phase III trial.

In November 2022, AstraZeneca’s IMFINZI (durvalumab) has been recommended for marketing authorization in the European Union (EU) for the 1st-line treatment of adult patients with unresectable or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin).

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the IMFINZI description, mechanism of action, dosage and administration, research and development activities in cholangiocarcinoma and malignant pleural mesothelioma.
• Elaborated details on IMFINZI regulatory milestones and other development activities have been provided in this report.
• The report also highlights the IMFINZI research and development activity in cholangiocarcinoma and malignant pleural mesothelioma in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around IMFINZI.
• The report contains forecasted sales of IMFINZI for cholangiocarcinoma and malignant pleural mesothelioma till 2032.
• Comprehensive coverage of the late-stage emerging therapies for cholangiocarcinoma and malignant pleural mesothelioma.
• The report also features the SWOT analysis with analyst views for IMFINZI in Cholangiocarcinoma.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

IMFINZI Analytical Perspective by DelveInsight

In-depth IMFINZI Market Assessment

This report provides a detailed market assessment of IMFINZI in cholangiocarcinoma and malignant pleural mesothelioma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

IMFINZI Clinical Assessment

The report provides the clinical trials information of IMFINZI in cholangiocarcinoma and malignant pleural mesothelioma covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for cholangiocarcinoma and malignant pleural mesothelioma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence IMFINZI dominance.
• Other emerging products for cholangiocarcinoma and malignant pleural mesotheliomaare expected to give tough market competition to IMFINZI and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of IMFINZI in cholangiocarcinoma and malignant pleural mesothelioma.
• Our in-depth analysis of the forecasted sales data from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the IMFINZI in cholangiocarcinoma and malignant pleural mesothelioma.

Key Questions

• What is the product type, route of administration and mechanism of action of IMFINZI?
• What is the clinical trial status of the study related to IMFINZI in cholangiocarcinoma and malignant pleural mesothelioma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the IMFINZI development?
• What are the key designations that have been granted to IMFINZI for cholangiocarcinoma and malignant pleural mesothelioma?
• What is the forecasted market scenario of IMFINZI for cholangiocarcinoma and malignant pleural mesothelioma?
• What are the forecasted sales of IMFINZI in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available in cholangiocarcinoma and malignant pleural mesothelioma and how are they giving competition to IMFINZI for Cholangiocarcinoma?
• Which are the late-stage emerging therapies under development for the treatment of cholangiocarcinoma and malignant pleural mesothelioma?